Drug Patents owned by Gw Res Ltd

1. List of Epidiolex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10195159 GW RES LTD Processes and apparatus for extraction of active substances and enriched extracts from natural products
May, 2022

(9 months ago)

US11096905 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Oct, 2035

(12 years from now)

US11207292 GW RES LTD Cannabidiol preparations and its uses
Apr, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9956186 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10092525 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9956183 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10111840 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10137095 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10603288 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10709671 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10709674 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9956184 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9956185 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9949937 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10849860 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10966939 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10709673 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US11154516 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US11311498 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US11357741 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US11446258 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10918608 GW RES LTD Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(12 years from now)

US11065209 GW RES LTD Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(12 years from now)

US11400055 GW RES LTD Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(12 years from now)

US11406623 GW RES LTD Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
Mar, 2041

(18 years from now)

US11160795 GW RES LTD Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
Mar, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2023
Orphan Drug Exclusivity (ODE) Jul 31, 2027
New Patient Population (NPP) Jul 31, 2023

Drugs and Companies using CANNABIDIOL ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of convulsive seizures in patients with lennox gastaut syndrome; Use for the treatment of drop seizures in patients with dravet syndrome; Use in combination with clobazam for the treatment of seizures in patients with lennox gastaut syndrome who have been previously treated with clobazam; Use in combination with clobazam for the treatment of seizures in patients with dravet syndrome who have been previously treated with clobazam; Use for the treatment of atonic seizures in patients with dravet syndrome; Use for the treatment of atonic seizures in patients with lennox-gastaut syndrome; Use for the treatment of drop seizures in patients with lennox-gastaut syndrome; Use in combination with clobazam for treatment of drop seizures in patients with lennox gastaut syndrome; Use for the treatment of seizures in patients with lennox-gastaut syndrome; Use for the treatment of seizures in patients with dravet syndrome; Use for reducing convulsive seizure frequency in patients with lennox gastaut syndrome; Use for reducing convulsive seizure frequency in patients with dravet syndrome; Use for the treatment of focal seizures in patients with dravet syndrome; Use in combination with clobazam for treatment of seizures in patients with lennox gastaut syndrome; Use for the treatment of convulsive seizures in patients with dravet syndrome; Use in combination with clobazam for the treatment of seizures in patients with dravet syndrome; Use for the treatment of seizures associated with dravet syndrome; Use for the treatment of seizures associated with lennox-gastaut syndrome; Use for the treatment of absence seizures in patients with dravet syndrome; Use for the treatment of absence seizures in patients with lennox-gastaut syndrome; Use for the treatment of seizures in patients with tuberous sclerosis complex; Use for the treatment of generalized seizures or focal seizures with impairment in patients with tuberous sclerosis complex; Use for reducing seizure frequency in patients with tuberous sclerosis complex; Use for the treatment of seizures associated with tuberous sclerosis complex in patients taking everolimus; Use for the treatment of seizures associated with tuberous sclerosis complex

Dosage: SOLUTION;ORAL

How can I launch a generic of EPIDIOLEX before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in